Citation Impact
Citing Papers
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Evaluation of platelet concentrates prepared from buffy coats and stored in a glucose‐free crystalloid medium
1989
5 Treatment and prognostic factors in acute myeloid leukaemia
1996
Disease relapse after haematopoietic stem cell transplantation: Risk factors and treatment
2007
Thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma
2004
Cyclosporine A-Associated Thrombotic Thrombocytopenic Purpura Following Lung Transplantation
1998
The biology of human natural killer-cell subsets
2001 Standout
Posterior Reversible Encephalopathy Syndrome, Part 1: Fundamental Imaging and Clinical Features
2008
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Neurotoxicity of calcineurin inhibitors: impact and clinical management
2000
Secondary leukemias induced by topoisomerase-targeted drugs
1998
Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia
2000
Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy
2000
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators
1999 Standout
Thrombotic Microangiopathy after Allogeneic Blood and Marrow Transplantation Is Associated with Dose-Intensive Myeloablative Conditioning Regimens, Unrelated Donor, and Methylprednisolone T-Cell Depletion
2004
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
Transplantation-associated thrombotic microangiopathy after steroid pulse therapy for polyserositis related to graft-versus-host disease
2010 StandoutNobel
Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
2008
Multiple myeloma
2000 Standout
Posterior Reversible Encephalopathy Syndrome, Part 2: Controversies Surrounding Pathophysiology of Vasogenic Edema
2008
Vascular disorders of the liver # †
2008 Standout
Non‐endocrine late complications of bone marrow transplantation in childhood: part II
2002
Chronic graft-versus-host disease
2003 Standout
Chronic Renal Failure after Transplantation of a Nonrenal Organ
2003 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Cyclosporin A Significantly Ameliorates Cortical Damage Following Experimental Traumatic Brain Injury in Rodents
1999
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group
2007
Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease
1999
Risk Factors and Severe Outcome in Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem Cell Transplantation
2006
Development, maintenance and disruption of the blood-brain barrier
2013 Standout
Detection of minimal residual disease
2001
Effect of Priming with Granulocyte Colony-Stimulating Factor on the Outcome of Chemotherapy for Acute Myeloid Leukemia
2003
Therapeutic apheresis in hematological and oncological diseases
2000
Graft-versus-host disease
2009 Standout
Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation
2006
Biology and management of relapsed acute myeloid leukaemia
2005
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
2010 Standout
Cancer treatment and survivorship statistics, 2012
2012 Standout
Pathophysiology and pharmacologic treatment of acute spinal cord injury*1
2004 Standout
Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation
2000
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
2003
Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma
2008
Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes
2001
Hepatic Venoocclusive Disease in Blood and Bone Marrow Transplantation in Children and Young Adults: Incidence, Risk Factors, and Outcome in a Cohort of 241 Patients
2002
Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria
2009
Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors
1994
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials
2015 Standout
Defining the Intensity of Conditioning Regimens: Working Definitions
2009 Standout
Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission.
1989 StandoutNobel
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
2010 Standout
Therapeutic Plasma Exchange in Patients with Grade 2–3 Hematopoietic Stem Cell Transplantation‐associated Thrombotic Thrombocytopenic Purpura: A Ten‐year Experience
2003
Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange
2009
Neurological and neuroradiological findings in long‐term survivors of allogeneic bone marrow transplantation
1998
Cancer as an evolutionary and ecological process
2006 Standout
Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A
2003
In Vitro Assessment of the Quality of Stored Platelet Concentrates
1994 Standout
Posttransplantation Thrombotic Thrombocytopenic Purpura: A Single-Center Experience and a Contemporary Review
2003
Cyclosporine-Induced Hypertension After Transplantation
1994
Sympathetic Neural Mechanisms of Cyclosporine-Induced Hypertension*
1996
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
1994
Traditional Chinese Medicines as Immunosuppressive Agents
2000
Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays
2000 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
2003 Standout
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)
2001
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
1999 StandoutScience
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
2001 Standout
Tacrolimus (FK 506) induced thrombotic thrombocytopenic purpura after ABO mismatched second liver transplantation: salvage with plasmapheresis and prostacyclin.
2000
Acute Myeloid Leukemia
2015 Standout
Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia
2002
Acute renal failure after myeloablative hematopoietic cell transplant: Incidence and risk factors
2004
Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation
2009
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
2009 Standout
FK506 in combination with methotrexate for the prevention of graft- versus-host disease after marrow transplantation from matched unrelated donors
1996
Primary dexamethasone treatment of multiple myeloma
1992
Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered
1999
New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
2004
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
1997
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
1998
A randomized placebo-controlled phase III study of granulocyte- macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)
1995
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns
2010
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
2001 Standout
Treatment of the Newly Diagnosed Adult with De Noyo Acute Myeloid Leukemia
1993
Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings
2000 StandoutNobel
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
2008 Standout
High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy
1990
In vivo hematopoietic stem cell modification by mRNA delivery
2023 StandoutScienceNobel
Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.
1993
An Updated Definition of Stroke for the 21st Century
2013 Standout
Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation
2001
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
1998 Standout
Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
1986
Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461
2004
Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemia
2001
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
Long-term survival of patients with acute myeloid leukemia
1997
Hematological Problems in Pediatric Intensive Care
2013 Standout
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
1996
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
1993
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
2013
Works of GP Herzig being referenced
High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results.
1989
Allogeneic marrow transplantation for refractory Hodgkin's disease.
1989
Severe cerebellar swelling and thrombotic thrombocytopenic purpura associated with FK506
1998
Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation
1999
High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study
1985
Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin.
1991
Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
1997
Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia
1996
Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia
1996
High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
1993
Correction of poor platelet transfusion responses with leukocyte-poor HL-A-matched platelet concentrates
1975
High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group
1995
High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy
1990